Strategies for sequencing PARP inhibitors are focused on the importance of genetic testing in advanced prostate cancer. Joseph Renzulli, MD, of Yale School of Medicine, elaborates. A new study ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

To date, standard targeted therapies in prostate cancer include PARP inhibitors, anti–PD-L1 therapy, and 177 Lu-PSMA-617, with several promising targeted agents currently under investigation. It is ...

DDR defects not only predispose to cancer, but also provide targets for therapy as a form of personalized medicine. PARP inhibitors target the DDR PARP enzymes support single strand break repair ...

Prostate cancer is the most common cancer in men ... with a view to starting them on PARP inhibitor treatment. In 340 cases, the men's cancer had spread elsewhere (metastasized).

Now, PARP inhibitors are something that we might all hear about when we treat for patients in ovarian cancer, breast cancer and pancreatic cancer, and the key is they need these genetic markers called ...

Alan H. Bryce, MD, discusses areas of need to help guide treatment decisions in the clinic for prostate cancer management.

Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...

In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake ...

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during ...

They also found that breast cancer cells that lose components of the complex that protects DNA from unnecessary DNA end cuts become resistant to chemotherapy drugs such as PARP inhibitors.

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...